texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Texas Oncology Joins Leading Global Gynecologic Cancer Research Group


For more information, contact:
Ed Bryson
512-495-7176
ed.bryson@fleishman.com
 

TEXAS ONCOLOGY JOINS LEADING GLOBAL GYNECOLOGIC CANCER RESEARCH GROUP

Austin physician named principal investigator for Texas Oncology in the Gynecologic Oncology Group, a national research group funded by the National Cancer Institute

AUSTIN, Texas (September 19, 2013) — Texas Oncology and US Oncology Research have been selected as a primary member of a national research cooperative, the Gynecologic Oncology Group (GOG). They join more than 50 leading cancer institutions in collaborating on major clinical and translational research funded by the National Cancer Institute (NCI). Created in 1970, the GOG is a collaborative group of gynecologic oncologists, medical oncologists, pathologists, nurses, research scientists, and other medical professionals, who focus on large scale national and international clinical trials in cancer of the ovary, uterus, and cervix.

“Providing our patients with access to the GOG’s extensive, independent, and collaborative research and clinical trials can help save lives in Texas, while also helping create treatment breakthroughs for women everywhere,” said Dr. Steven Paulson, chairman and president of Texas Oncology. “This is an important and clear testament to the quality and depth of experience in gynecologic cancer treatment at Texas Oncology, and our significant commitment to research and clinical trials.”

The GOG has grown from 11 original institution members to more than 50 principal centers, and includes more than 2,100 participating medical professionals. Considered the world’s foremost multidisciplinary cooperative clinical trial research group devoted to gynecologic malignancies (women’s cancers), the group has completed more than 300 clinical trials, and currently enrolls more than 3,300 women each year in clinical trials.

Texas Oncology in Austin was selected as a primary member institution, with affiliate designations for Texas Oncology in Fort Worth, Houston, and Dallas and for The US Oncology Network’s Arizona Oncology locations in Phoenix and Tucson. Women in these areas will no longer have to travel to have access to NCI-sponsored trials, enabling them to stay close to the critical support of family and friends.

The membership election took place at the GOG annual meeting in San Antonio. Austin-based gynecologic oncologist Michael Teneriello, M.D., was named lead principal investigator, with Noelle Cloven, M.D., Texas Oncology–Fort Worth 12th Ave. serving as co-principal investigator.

“It is important for patients in community-based treatment settings across Texas to have access to the highest caliber gynecologic cancer clinical research trials – and not only in major academic institutions – since more than 80 percent of all cancer care is now community based,” said Dr. Michael Teneriello, gynecologic oncologist, Texas Oncology–South Austin, Austin Central, and Waco. “It is an honor for our physicians and staff to be invited to participate in the GOG. We are excited about the opportunity that GOG membership offers for our patients throughout Texas Oncology to participate in groundbreaking clinical research trials.”

About Texas Oncology
Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve “More breakthroughs. More victories.”® in their fights against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology participates in innovative clinical trials from Phase I through Phase IV through US Oncology Research, which has helped to develop 46 FDA approved cancer therapies.

Texas Oncology is united in healing with The US Oncology Network, one of the nation’s largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Texas Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. The US Oncology Network is supported by McKesson Specialty Health.

For more information, visit www.TexasOncology.com or call 1-888-864-I CAN (4226).

###